Search the Newsreel

Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Teva Pharmaceutical Industries reported record quarterly UZEDY sales, with a significant year over year …

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

Teva Pharmaceutical Industries Limited TEVA reported second-quarter 2026 adjusted earnings of 2 cents per share, which missed the Zacks Consensus Estimate of 8 cents. Adjusted earnings declined 97% year over year due to higher acquisition costs. Adjusted earnings included an impact of a loss …

Is Teva Pharmaceutical Industries (TEVA) A Bargain After Results And Higher Revenue Guidance?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting second quarter 2026 results, combining a reported net loss of US$576 million with …

Stevanato’s Alina pen injector gains EU approval for liraglutide

Stevanato Group S.p.A. announced that its Alina pen injector platform has received marketing authorizations in Europe for liraglutide-based combination products. The approval covers Alina 30 for diabetes therapies and Alina 50 for weight management. The Alina platform is a variable-dose, disposable pen injector designed …

Is Teva (TEVA) Trading Profit for Future Potential With Its Branded‑Drug Pivot?

In the past week, Teva Pharmaceutical Industries reported Q2 2026 results showing largely flat sales of US$4,142 million year-on-year but shifting from net income of US$282 million to a net loss of US$576 million, driven in part by impairment charges and acquisition-related costs. Despite …

Diabetes and weight-management products using Alina gain European authorizations

Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management. The approvals for Alina® 30 and Alina® 50 variants highlight the growing demand for injectable therapies, particularly GLP-1 treatments, and …

Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European Countries

Stevanato Group announced that its liraglutide-based combination products, incorporating the proprietary Alina pen injector, have received marketing authorizations in Europe. These authorizations cover both Alina 30 for diabetes and Alina 50 for weight management, supporting the growing demand for injectable therapies like GLP-1 treatments. …

Teva CEO on Drug Pipeline, Direct Listing on NYSE

Teva Pharmaceuticals CEO Richard Francis speaks to Bloomberg's Romaine Bostick about the company's positive Q2 earnings, the impending impact of changing Medicare rules on patients, and the new listing on the NYSE. View Comments

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

This article first appeared on GuruFocus. Revenue: Approximately $4.1 billion, down 1% in U.S. Dollars or 3% in local currency compared to Q2 2025. Net Loss: $576 million. Non-GAAP Gross Margin: 55.4%, an increase of 80 basis points year-over-year. Non-GAAP Operating Margin: 9%, including …

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents …

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

Teva stock advances after the pharmaceutical company reports mixed second-quarter earnings but raises its full-year revenue outlook. Continue Reading

Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Teva Pharmaceutical Industries Ltd. (TEVA) reported $4.14 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 0.8%. EPS of $0.02 for the same period compares to $0.66 a year ago. The reported revenue represents a surprise of +1.43% over …

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

MONTPELLIER, France, July 29, 2026--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 …

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Teva Pharmaceutical Industries Ltd Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over …

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

For decades, pharmaceutical advertising largely revolved around television commercials urging patients to ask their doctors about branded medication. Increasingly, however, drugmakers are investing in a different kind of marketing campaign—one built around trusted athletes who have publicly discussed their own health struggles. The latest …

Teva Stock Is Rebounding. Its Drug Pipeline Holds the Key to Growth.

Teva can look beyond President Donald Trump’s threat of a tariff on generic drugs. Teva has a pipeline of branded drugs that has caught Wall Street’s attention. Continue Reading

Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics

In its upcoming report, Teva Pharmaceutical Industries Ltd. (TEVA) is predicted by Wall Street analysts to post quarterly earnings of $0.08 per share, reflecting a decline of 87.9% compared to the same period last year. Revenues are forecasted to be $4.1 billion, representing a …

Stevanato Group SpA (STVN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Stevanato Group SpA (STVN), listing major institutional holders and their respective proportions. Key shareholders include Conestoga Capital Advisors, LLC, Neuberger Berman, LLC, and T. Rowe Price Investment Management, Inc. The report also provides a breakdown of shareholder …

Stevanato Group Spa (STVN) Q1 2023 Earnings Report - Results, Call & Slides

Stevanato Group (STVN) reported its Q1 2023 earnings, missing both EPS and revenue estimates. The company posted an actual EPS of $0.13 against a consensus of $0.14, and revenue of $255.35M compared to an expected $267.16M, though still achieving a YoY revenue growth of …

STVN|Stevanato Group SpA|Price:19.390|Chg%:+0.020

Stevanato Group SpA (STVN) is experiencing healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. The stock is rated as a "Buy" by multiple analysts, with a target price of 25.175, indicating a significant …

Price-Driven Insight from (STVN) for Rule-Based Strategy

This article provides a price-driven insight for Stevanato Group S.p.a. (NASDAQ: STVN) based on AI models from Stock Traders Daily. It highlights near-term weak sentiment, no clear price positioning signal, and compelling upside potential due to a lack of resistance levels. The report also …

Stevanato Group (STVN) Bank of America Global Healthcare Conference 2026 Summary

Stevanato Group (STVN) presented at the Bank of America Global Healthcare Conference 2026, highlighting its long-term customer partnerships due to high switching costs and regulatory integration, driving strong organic growth through high-value solutions like Nexa syringes. The company emphasized its growth drivers in biologics …

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

Stevanato Group S.p.A. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 6:30 a.m. EDT. The company will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss the results, with …

Stevanato Group schedules Aug. 4 results webcast at 8:30 a.m.

Stevanato Group (STVN) Investor presentation Summary

Stevanato Group (STVN) presented an investor summary highlighting its operational excellence, market leadership, and strong financial performance. The company has a global footprint, a high-value solutions (HVS) portfolio driving significant revenue growth, and is benefiting from secular tailwinds in the biopharma industry. Future guidance …

Stevanato Group S.p.A. $STVN Stock Holdings Lifted by Van Berkom & Associates Inc.

Van Berkom & Associates Inc. significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 2,944.2% in the first quarter, now holding 170,994 shares valued at $2.35 million. This move comes despite the company missing Q1 earnings estimates, though revenue rose 6.6% year-over-year. Analysts …

Roubaix Capital LLC Has $5.30 Million Holdings in Stevanato Group S.p.A. $STVN

Roubaix Capital LLC significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 96.6% in the first quarter, now holding 385,316 shares valued at $5.3 million. Despite Stevanato Group missing Q1 EPS expectations, analysts maintain a constructive outlook, with recent upgrades and an outperform …

STVN Q1 2026 Earnings: EPS Beats Estimates, Stock Declines Amid Lack of Revenue Detail - Earnings Deceleration Risk

Stevanato Group (STVN) Earnings Date and Reports 2026

Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results